The Company’s investments consist of the following (in thousands): | | | | | | | | | | | | | | | | June 30, 2026 | Investee | | Investment Type | | Ownership Percentage | | Carrying Value | | Cost Basis | Reogen | | Equity Method Investment | | 39.0 | % | | $ | 26,276 | | $ | 98,178 | Hologen Limited | | Equity Investment | | 3.0 | % | | | 6,813 | | | 6,813 | Visiogene LLC | | Equity Method Investment | | 25.0 | % | | | 5,133 | | | 5,165 | Other | | Equity Investment | | 0.8 | % | | | 1,616 | | | 1,500 | Total equity method and other investments | | | | | | | $ | 39,838 | | $ | 111,656 |
| | | | | | | | | | | | | | | | December 31, 2025 | Investee | | Investment Type | | Ownership Percentage | | Carrying Value | | Cost Basis | Visiogene LLC | | Equity Method Investment | | 25.0 | % | | $ | 5,133 | | $ | 5,165 | Other | | Equity Investment | | 0.8 | % | | | 1,616 | | | 1,500 | Total equity method and other investments | | | | | | | $ | 6,749 | | $ | 6,665 |
Below is the summarized financial information of Reogen for the period between April 20, 2026 and June 30, 2026 (in thousands): | | | | | | | | For the period between | | | April 20, 2026 and June 30, 2026 | Statement of Operations | | | | | | Research and development expense | | $ | | | (184,381) | General and administrative expense | | $ | | | (20) | Other income | | $ | | | 43 | Net loss | | $ | | | (184,358) |
|